Results 51 to 60 of about 2,540,555 (296)

MANAGEMENT OF TYPE 2 DIABETES

open access: yesHealth Problems of Civilization
Type 2 diabetes mellitus (T2DM) is the more common form of diabetes, characterized by insulin resistance and reduced insulin secretion; this occurs during the progression of T2DM, and high blood glucose levels.
Maitham Abdallah Albajy   +1 more
doaj   +1 more source

Simvastatin Use in Patients with Type 2 Diabetes Mellitus: The Effects on Oxidative Stress

open access: yesOman Medical Journal, 2015
Objectives: Studies have shown that people with type 2 diabetes mellitus (T2DM)may develop atherosclerosis due to the disturbance in oxidative control and progressive dyslipidemia.
Mohammad A. Abdelhussein   +3 more
doaj   +1 more source

Colorectal cancer‐derived FGF19 is a metabolically active serum biomarker that exerts enteroendocrine effects on mouse liver

open access: yesMolecular Oncology, EarlyView.
Meta‐transcriptome analysis identified FGF19 as a peptide enteroendocrine hormone associated with colorectal cancer prognosis. In vivo xenograft models showed release of FGF19 into the blood at levels that correlated with tumor volumes. Tumoral‐FGF19 altered murine liver metabolism through FGFR4, thereby reducing bile acid synthesis and increasing ...
Jordan M. Beardsley   +5 more
wiley   +1 more source

Reversal of Type 2 Diabetes Mellitus

open access: yesRUHS Journal of Health Sciences, 2023
NA
Sudhir Bhandari
doaj   +1 more source

Identification of serum protein biomarkers for pre‐cancerous lesions associated with pancreatic ductal adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This work identified serum proteins associated with pancreatic epithelial neoplasms (PanINs) and early‐stage PDAC. Proteomics screens assessed genetically engineered mice with abundant PanINs, KPC mice (Lox‐STOP‐Lox‐KrasG12D/+ Lox‐STOP‐Lox‐Trp53R172H/+ Pdx1‐Cre) before PDAC development and also early‐stage PDAC patients (n = 31), compared to benign ...
Hannah Mearns   +10 more
wiley   +1 more source

Typ-2-Diabetes [PDF]

open access: yesMMW - Fortschritte der Medizin, 2010
Patienten mit Diabetes mellitus Typ 2 fragen haufig nach einer natur-heilkundlichen Alternative zur regelmasigen Einnahme von chemisch definierten Antidiabetika. Grundsatzlich ist jedoch festzuhalten, dass eine naturheilkundliche Diabetestherapie nur adjuvant zu der leitlinien-konformen Therapie durchgefuhrt werden sollte.
openaire   +2 more sources

Patient and provider acceptance of telecoaching in type 2 diabetes : a mixed-method study embedded in a randomised clinical trial [PDF]

open access: yes, 2016
Background: Despite advances in diagnosis and treatment of type 2 diabetes, suboptimal metabolic control persists. Patient education in diabetes has been proved to enhance self-efficacy and guideline-driven treatment, however many people with type 2 ...
Aertgeerts, Bert   +6 more
core   +3 more sources

RIPK4 function interferes with melanoma cell adhesion and metastasis

open access: yesMolecular Oncology, EarlyView.
RIPK4 promotes melanoma growth and spread. RIPK4 levels increase as skin lesions progress to melanoma. CRISPR/Cas9‐mediated deletion of RIPK4 causes melanoma cells to form less compact spheroids, reduces their migratory and invasive abilities and limits tumour growth and dissemination in mouse models.
Norbert Wronski   +9 more
wiley   +1 more source

Fetal Brain Tumor Harboring a Unique ROCK1::BRAF Fusion

open access: yes
Pediatric Blood &Cancer, EarlyView.
Marllon Cindra Sant'Ana   +8 more
wiley   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

open access: yesMolecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy